<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> increases the risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and may be associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We tested the hypothesis that the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> confers risk with or without concomitant <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> among 2,803 Framingham Offspring Study subjects followed up to 11 years for new <z:mp ids='MP_0002055'>diabetes</z:mp> (135 cases) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (240 cases) </plain></SENT>
<SENT sid="2" pm="."><plain>We classified subjects by presence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (using the National Cholesterol Education Program's [NCEPs] Third Adult Treatment Panel [ATP III], International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation [IDF], or European Group for the Study of <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo> [EGIR] criteria) and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> &gt; or = 75th percentile) and used separate risk factor-adjusted proportional hazards models to estimate relative risks (RRs) for <z:mp ids='MP_0002055'>diabetes</z:mp> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> using as referents those without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, or without both </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Fifty-six percent of individuals with ATP III, 52% with IDF, and 100% with EGIR definitions of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> had <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> increased risk for <z:mp ids='MP_0002055'>diabetes</z:mp> (RR 2.6 [95% CI 1.7-4.0]) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (1.8 [1.4-2.3]) as did <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> for <z:mp ids='MP_0002055'>diabetes</z:mp> (ATP III, 3.5 [2.2-5.6]; IDF, 4.6 [2.7-7.7]; and EGIR, 3.3 [2.1-5.1]) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (ATP III, 1.8 [1.4-2.3]; IDF, 1.7 [1.3-2.3]; and EGIR, 2.1 [1.6-2.7]) </plain></SENT>
<SENT sid="5" pm="."><plain>Relative to those without either <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> or <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> increased risk for <z:mp ids='MP_0002055'>diabetes</z:mp> (ATP III, 6.0 [3.3-10.8] and IDF, 6.9 [3.7-13.0]) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (ATP III, 2.3 [1.7-3.1] and IDF, 2.2 [1.6-3.0]) </plain></SENT>
<SENT sid="6" pm="."><plain>Any instance of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> increased risk for <z:mp ids='MP_0002055'>diabetes</z:mp> approximately threefold (P &lt; 0.001); IDF <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (RR 1.6, P = 0.01), but not ATP III <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (RR 1.3, P = 0.2), increased risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> increased risk for <z:mp ids='MP_0002055'>diabetes</z:mp> regardless of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> by ATP III criteria may require <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> to increase risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The simultaneous presence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> identifies an especially high-risk individual </plain></SENT>
</text></document>